[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353798-105":59,"doc-detail-353798-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-progress-on-tumor-associated-macrophages-and-pd-1pd-l1-inhibitors-in-advanced-colorectal-cancer-cancer-control-volume-33-1-17","Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer - Cancer Control Volume 33 - 1-17","","Colorectal cancer (CRC) is a highly prevalent malignancy and a leading cause of cancer-related death worldwide. Although surgical resection is central for curative care, advanced CRC continues to face high rates of postoperative recurrence and metastasis. Immune checkpoint inhibitors, especially PD-1/PD-L1 monoclonal antibodies, show limited benefit in CRC largely due to mismatch repair status. Tumor-associated macrophages (TAMs) regulate the tumor immune microenvironment by suppressing immunity and driving PD-1 expression on tumor cells, contributing to resistance to PD-1/PD-L1 blockade. This narrative review summarizes emerging mechanistic insights and discusses clinical limitations while proposing future research directions, including strategies that improve immunotherapy responsiveness through TAM modulation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-progress-on-tumor-associated-macrophages-and-pd-1pd-l1-inhibitors-in-advanced-colorectal-cancer-cancer-control-volume-33-1-17/353798/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-progress-on-tumor-associated-macrophages-and-pd-1pd-l1-inhibitors-in-advanced-colorectal-cancer-cancer-control-volume-33-1-17/353798.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do PD-1/PD-L1 inhibitors have limited clinical benefit in advanced colorectal cancer?","Question",{"text":112,"@type":113},"Their benefit is constrained by mismatch repair (MMR) status, leaving most proficient MMR/microsatellite stable (pMMR/MSS) patients with minimal therapeutic gain.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What roles do tumor-associated macrophages (TAMs) play in resistance to PD-1/PD-L1 blockade?",{"text":117,"@type":113},"TAMs exert immunosuppressive effects through PD-1 and multiple other pathways and can promote PD-1 expression on tumor cells via distinct mechanisms, contributing to treatment resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review aim to do regarding TAM modulation and immunotherapy?",{"text":121,"@type":113},"It summarizes the latest advances on TAM involvement in resistance to PD-1/PD-L1 inhibitors, highlights strategies to enhance responsiveness through TAM modulation, and discusses limits of current clinical studies with future research directions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353798,1790674718,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer | Cancer Control Volume 33: 1–17 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/10732748261430581](DOI: 10.1177/10732748261430581)\u003Cbr>[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Shihao Ning1,* , Huiming Wu1,*, Renkai Guo1, Min Deng1, Yipeng Cui1, Dingwen Xue1, Chunchen Li1, Chenfei Jin1, and Huiyu Li1\u003Cbr>Abstract\u003Cbr>Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related mortality worldwide. Currently, surgical resection remains the cornerstone of curative treatment for CRC; however, patients with advanced disease continue to face significant risks of postoperative recurrence and metastasis. Although immune checkpoint inhibitors (ICIs), represented by PD-1/PD-L1 monoclonal antibodies, have reshaped the therapeutic landscape of various solid tumors, their clinical benefit in CRC is strictly limited by mismatch repair (MMR) status, leaving the vast majority of proficient mismatch repair/microsatellite stable (pMMR/MSS) patients with minimal therapeutic gain. Importantly, tumor-associated macrophages (TAMs)—a key regulatory component of the tumor immune microenvironment—not only exert immunosuppressive functions through PD-1 and multiple other pathways, but also promote PD-1 expression on tumor cells via distinct mechanisms. Consequently, accumulating evidence suggests that TAMs play a critical role in mediating resistance to PD-1/PD-L1 inhibitors in CRC. Nevertheless, research on the underlying mechanisms remains at an early stage. This narrative review aims to summarize the latest advances regarding the involvement of TAMs in resistance to PD-1/PD-L1 blockade, with a particular focus on strategies to enhance immunotherapy responsiveness through TAM modulation. We further discuss limitations in current clinical studies and propose potential directions for future research. By juxtaposing successful mechanistic studies with underwhelming clinical trial data, we aim to redefine the therapeutic rationale for combining TAM-targeted agents with immune checkpoint blockade.\u003Cbr>Plain Language Summary\u003Cbr>Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, and its treatment outcomes are strongly influenced by the tumor immune microenvironment (TIME) . Macrophages are immune cells that act as the body’s“cleaners” and “regulators”, but within tumors, they are often “recruited” to support cancer growth and spread. These cells are known as tumor-associated macrophages (TAMs) . This review summarizes key recent studies on TAMs in colorectal cancer, including findings from both experimental and clinical research. Evidence shows that TAMs contribute to tumor growth, angiogenesis, and immune evasion, and may also affect the response to immunotherapies such as PD-1/PD- |  |\n| 1Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Shanxi Bethune Hospital, Taiyuan, Shanxi, China\u003Cbr>*Shihao Ning and Huiming Wu have equal contributions to this article.\u003Cbr>Corresponding authors:\u003Cbr>Huiyv Li, Department of General Surgery, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Shanxi Bethune Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan, Shanxi 030032, China.\u003Cbr>Email: [lihuiyu@sxbqeh.com.cn](lihuiyu@sxbqeh.com.cn)\u003Cbr>Shihao Ning, Department of General Surgery, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Shanxi Bethune Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan, Shanxi 030032, China.\u003Cbr>Email: [250162020200050@sxmu.edu.cn](250162020200050@sxmu.edu.cn) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is dist","cbCaium7fQYc2WNo","https://ap.wps.com/l/cbCaium7fQYc2WNo","pdf",4019643,17,"English","# Abstract\n# Plain Language Summary\n# Keywords\n# Background\n## Colorectal cancer epidemiology and treatment challenges\n## Immune checkpoint inhibitors and mismatch repair limitations\n## TAMs and resistance mechanisms","[{\"question\":\"Why do PD-1/PD-L1 inhibitors have limited clinical benefit in advanced colorectal cancer?\",\"answer\":\"Their benefit is constrained by mismatch repair (MMR) status, leaving most proficient MMR/microsatellite stable (pMMR/MSS) patients with minimal therapeutic gain.\"},{\"question\":\"What roles do tumor-associated macrophages (TAMs) play in resistance to PD-1/PD-L1 blockade?\",\"answer\":\"TAMs exert immunosuppressive effects through PD-1 and multiple other pathways and can promote PD-1 expression on tumor cells via distinct mechanisms, contributing to treatment resistance.\"},{\"question\":\"What does the review aim to do regarding TAM modulation and immunotherapy?\",\"answer\":\"It summarizes the latest advances on TAM involvement in resistance to PD-1/PD-L1 inhibitors, highlights strategies to enhance responsiveness through TAM modulation, and discusses limits of current clinical studies with future research directions.\"}]","Research Progress on Tumor-Associated Macrophages and PD-1/PD-L1 Inhibitors in Advanced Colorectal Cancer - Cancer Control Volume 33 - 1-17 | PDF",1790107298,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96fd6e4ee4d5d9417cb70f41d153b7c7.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c21a41479b37d31bf77643ae587b95c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f394ae31386502838d609aef8e87e94e.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0081eef3b51ea0dcd3e4ce9533381091.webp",980,1306]